Precision aptamers
for aggressive cancers.

Our Technology

Technology

Aptadel Therapeutics uses aptamers as a platform to deliver therapeutic agents with high specificity and improved safety to treat a wide variety of cancers.

Unlocking the Next Generation of
Precision Medicine with Aptamers

Aptadel Therapeutics innovative technology counteracts metastasis and delivers therapeutic agents to cancer cells with exceptional precision. This powerful, dual-action approach is engineered to confront cancer at early and advanced stages.

Technology Strengths

Icon Drawing flower

Outstanding affinity and specificity for cancer cells

Icon Drawing flower

High tumour penetration

Icon Drawing flower

Facile and flexible manufacturing

Icon Drawing flower

Modular platform for drug delivery

Changing The Way We Treat Cancer

Laboratory with orange gradient

The receptor tyrosine kinase EphA2 promotes tumour growth and metastasis and is overexpressed in cancer cells but not in normal tissue

EphA2 is located at the plasma membrane, being highly accessible for therapeutics.

Aptadel Therapeutics developed anti-EphA2 RNA aptamers that inhibit the metastatic potential of tumoral cells and deliver intracellularly cytotoxic drug cargoes to target local and disseminated tumours.

The result are highly efficacious compounds with unprecedented safety profile acting on tumor cells while leaving healthy cells unharmed

Scientific Publications

“Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis”.

Chicón-Bosch M, et al.
Mol Oncol 2025. 19: 1022-1028.

View Publication

“The future of aptamers in cancer diagnosis, prognosis and treatment”.

Arévalo J and Torres AG.
Expert Opin Biol Ther 2024. 24: 873-877.

View Publication

“Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors”.

Santana-Viera L, et al.
Mol Ther Nucleic Acids 2023. 32: 758-772.

View Publication

“EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma”.

Garcia-Monclús S, et al.
Int J Cancer. 2018. 143: 1188-1201.

View Publication

The Company

Icon Drawing flower

Aptadel Therapeutics, a spin-off from IDIBELL, emerging form de Sarcoma's group led by Dr. Oscar Martínez-Tirado. The company was born from a deep commitment to advancing research in paediatric cancer, particularly Ewing sarcoma.

Icon Drawing flower

Aptadel Therapeutics has expanded its vision and consolidated a robust platform to develop targeted therapies for both paediatric and adult cancers.

We aim to bring the precision of aptamers across every stage of life, from paediatric oncology to highly aggressive adult cancers

Icon Drawing flower

At its core, Aptadel Therapeutics embodies disruptive science with a clear purpose to improve the quality of life of patients. Through its next-generation technology, Aptadel Therapeutics is reshaping how cancer is treated: with precision, safety and hope.

Pipeline

  • Program
  • Discovery
  • Lead Optimization
  • Preclinical
  • Clinical

ADEL-001

Anti-MetastasicDrug
Metastasic cancers

ADEL-101

Aptamer-siRNA
Ewing Sarcoma

ADEL-102

Aptamer-siRNA
Rhabdomyosarcoma

ADEL-201 (Partnered programms)

Diagnostic Kit

ADEL-301 (Partnered programms)

Radioconjugate
Solid tumors

ADEL-401 (Partnered programms)

Aptamer-NPs
Solid tumors

ADEL-501 (Partnered programms)

Aptamer-ASO
Solid tumors

Leadership

Our team is composed of experts in the field of life sciences and a track record in Biotech Companies

Leadership Team

Gisela Lorente AptadalTX

Gisela Lorente, PhD

CEO

LinkedIn Icon
Adrián Torres AptadalTX

Oscar Martínez-Tirado, PhD

Academic Founder

LinkedIn Icon
Nadia Pons AptadalTX

Nadia Pons, MSc

COO

LinkedIn Icon
Adrián Torres AptadalTX

Adrián Torres, PhD

CSO

LinkedIn Icon

Supported By

Aptadel is supported by academic foundations, patient associations and competitive grants from national and international agencies.

Discover all the supporters

Contact

Our location

Parc Cientific Barcelona (PCB)
C/ Baldiri Reixac 4 08028,
Barcelona (Spain)

Our e-mail

info@aptadeltx.com